Related Experiment Video
Updated: Dec 29, 2025

Confocal Microscopy Reveals Cell Surface Receptor Aggregation Through Image Correlation Spectroscopy
Published on: August 2, 2018
The Dark Side of Gefitinib: Reflectance Confocal Microscopy Applied to Hair Hyperpigmentation
Terenzio Cosio1, Sara Mazzilli1, Luca Bianchi1
1Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Abstract:
Gefitinib is a multi-target tyrosine kinase inhibitor used for the treatment of non-small cell lung cancer. Papulo-pustular and/or paronychia, abnormalities in hair growth, itching, and dryness due to epidermal growth factor inhibitors - i.e., PRIDE Complex - are a common effect of tyrosine kinase inhibitors. We report a case of hair and eyebrow hyperpigmentation after 7 months of treatment with gefitinib. In the literature, we found no data regarding rapid pigmentation of hair due to treatment with any multi-target tyrosine kinase inhibitors. To our knowledge, this is the first case reporting both hair and eyebrow hyperpigmentation. We hypothesize the role of different mechanisms linked to rapid hair hyperpigmentation.
Insights
Gefitinib, a lung cancer drug, can cause skin issues. This report details a rare case of hair and eyebrow hyperpigmentation, a side effect not previously documented with this medication.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Gefitinib is a tyrosine kinase inhibitor used for non-small cell lung cancer.
- Tyrosine kinase inhibitors can cause skin side effects, known as PRIDE Complex.
- PRIDE Complex includes papulo-pustular rash, paronychia, hair abnormalities, itching, and dryness.
Observation:
- A case study of a patient treated with gefitinib is presented.
- The patient developed hyperpigmentation of hair and eyebrows after 7 months of gefitinib treatment.
- This specific side effect was observed over a prolonged treatment period.
Findings:
- This is the first reported case of hair and eyebrow hyperpigmentation associated with gefitinib treatment.
- No previous literature documented rapid hair pigmentation from multi-target tyrosine kinase inhibitors.
- The study highlights an unusual dermatological manifestation of gefitinib therapy.
Implications:
- This finding expands the known side effect profile of gefitinib.
- Further research is needed to understand the mechanisms behind gefitinib-induced hair hyperpigmentation.
- Clinicians should be aware of this potential, albeit rare, side effect in patients undergoing gefitinib treatment.
More Related Videos
09:37Combining Reflectance Confocal Microscopy with Optical Coherence Tomography for Noninvasive Diagnosis of Skin Cancers via Image Acquisition
Published on: August 18, 2022
06:41A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
Published on: March 9, 2015